Pain scale

Advanced Health Assessment & Clinical Diagnosis in Primary Care. Edition No. 7 - ResearchAndMarkets.com

Retrieved on: 
Friday, November 4, 2022
Health, General Health, Doctor of Nursing Practice, Patient, Pandemic, Minnesota Advanced Practice Registered Nursing, MST, MD Anderson Cancer Center, History, Population, Epidemic, Compact, Pain scale, Veteran, Gender identity, Health promotion, Pediatrics, COVID-19, Differential diagnosis, TGD, University, Diagnosis, Military sexual trauma, Physical examination, Veterans Health Administration, Health, APN, Transgender, Content, Medical imaging, Medical device, Medicine, Sex industry, Hospital

The "Advanced Health Assessment & Clinical Diagnosis in Primary Care.

Key Points: 
  • The "Advanced Health Assessment & Clinical Diagnosis in Primary Care.
  • Take the next step in health assessment by building your skills in diagnostic and clinical reasoning!
  • Advanced Health Assessment & Clinical Diagnosis in Primary Care, 7th Edition goes beyond the basic physical examination to help you learn to accurately evaluate common conditions.
  • - Clear, consistent diagnostic reasoning process takes you to the next step of health assessment - beyond basic history and physical examination to diagnostic reasoning and clinical diagnosis.

Align Helps Women Find Balance With Women’s Dual Action Probiotic -Targeting Both Gut and Vaginal Health in One

Retrieved on: 
Thursday, November 3, 2022
Vitamins, Supplements, Women, Other Health, Consumer, Health, Criticism of the Food and Drug Administration, International Flavors & Fragrances, Research, Pain scale, Multimedia, Food, Bifidobacterium, Nutritional science, Overalls, New Women, Woman, Gastroenterology, Vitex, Human milk microbiome, Bacteria, Ambi, View, P&G, Probiotic, Pressure, Health, Immune system, Disease, Federal Firearms License, News, Aroma compound, Bloating, Human, Dietary supplement, Birth control, Align

Align Probiotic, the #1 doctor recommended probiotic brand, is educating women on the connection between gut and vaginal health with the launch of their Womens Dual Action Probiotic.

Key Points: 
  • Align Probiotic, the #1 doctor recommended probiotic brand, is educating women on the connection between gut and vaginal health with the launch of their Womens Dual Action Probiotic.
  • Align Womens Dual Action Probiotic was developed with proven, well-researched ingredients to support womens digestive and vaginal health by Senior Scientist Chelsay Brewster and her team after speaking to real women and seeing a gap in the market for their needs.
  • When taken daily, Align Women's Dual Action helps soothe occasional digestive upsets like bloating, gas, and abdominal discomfort* with their unique strain, Bifidobacterium 35624.
  • Women not only have a gut microbiome but a vaginal microbiome as well, both of which impact overall balance, said Chelsay Brewster.

Clinical Study by Salem Pain Clinic, Surrey, Canada, Shows That Facial Topical Cream Enhances Facemask Tolerability and Compliance During the COVID-19 Pandemic

Retrieved on: 
Tuesday, November 1, 2022
People, Bruise, Zinc oxide, GLOBE, Research, Pain scale, COVID-19, Ulcer, Insomnia, Rash, Dermatitis, Compliance, Red, Hotness, Graham cracker crust, Acne, Pachycormus discolor, Skin, Journal, Infection, Dentistry, Cosmetics

SURREY, British Columbia, Nov. 01, 2022 (GLOBE NEWSWIRE) -- A clinical research study has shown that facial topical cream promotes facemask tolerability and compliance during the COVID-19 pandemic.

Key Points: 
  • SURREY, British Columbia, Nov. 01, 2022 (GLOBE NEWSWIRE) -- A clinical research study has shown that facial topical cream promotes facemask tolerability and compliance during the COVID-19 pandemic.
  • The reputable research was led and authored by Dr. Olu Bamgbade at the Salem Pain Clinic in Surrey, British Columbia, Canada.
  • Dr. Bamgbade is the director of the Salem Pain Clinic, a specialist pain clinic and research centre( https://salempainclinic.net/ ).
  • People who experience facial redness from facemasks should treat their skin with topical hydrocortisone or diphenhydramine cream," advised Dr. Bamgbade.

Data Presented at Obesity Week Demonstrate that Gelesis Investigational Clinical-Stage Oral Superabsorbent Hydrogel Gel-B Preferentially Enhances the Growth of Akkermansia muciniphila in Preclinical Models Compared to Prebiotics

Retrieved on: 
Wednesday, November 2, 2022
Oncology, Health, Diabetes, Fitness & Nutrition, General Health, Clinical Trials, Pharmaceutical, Security (finance), Human, Inulin, Nature, Growth, Type 2 diabetes, Failure, Annual report, Humanitas University, Nutritional science, NAFLD, Abdomen, Gel, U.S. Securities and Exchange Commission, Obesity, GLS, Exercise, Diet, 100,000, XXV, Patient, NYSE, Diarrhea, Risk, Industry, COVID-19, Functional constipation, Bacteria, Intellectual property, Flatulence, Psyllium, Use, Non-alcoholic fatty liver disease, Absorption, Revlon, Inc. v. MacAndrews & Forbes Holdings, Inc., Body mass index, Defecation, Gelatin, Incidence, NASH, BMI, Social media, Food, Perception, FDA, Elasticity, Allergy, Pain scale, Cellulose, Multimedia, Social conditioning, New, Environment, Forward-looking statement, Citric acid, Gum arabic, Dietary supplement, Risk management, Hydrogel

Gelesis Holdings Inc. (NYSE: GLS) (Gelesis or the Company) the maker of Plenity for weight management, today released new data at Obesity Week in San Diego.

Key Points: 
  • Gelesis Holdings Inc. (NYSE: GLS) (Gelesis or the Company) the maker of Plenity for weight management, today released new data at Obesity Week in San Diego.
  • The group found that A. muciniphila grows in the presence of Gel-B as early as two weeks post-treatment.
  • These data are an important step forward in understanding how oral superabsorbent hydrogels induce beneficial changes to the microbiome.
  • We are looking forward to conducting further studies in this area to understand how these changes will translate to humans, said Elaine Chiquette, Gelesis Chief Scientific Officer.

EQS-News: See What’s Next For The Regenerative Medicine Field -- BioRestorative Intends to Lead The Pack In Stem Cell Therapies!

Retrieved on: 
Monday, October 31, 2022
Human, Insurance, Degenerative disease, Metabolism, Death, Pain, Obesity, Regenerative medicine, Pain scale, Stem cell, Environment, Diabetes, Extracellular matrix, Solution, Hip, Survival rate, Patient, Back pain, Adipose tissue, Risk, IPS, Advertising, Cell, Extremities, NASDAQ, Traction, FDA, Probability, Scoliosis, HES, Science, Pharmaceutical industry, Dentistry

See Whats Next For The Regenerative Medicine Field -- BioRestorative Intends to Lead The Pack In Stem Cell Therapies!

Key Points: 
  • See Whats Next For The Regenerative Medicine Field -- BioRestorative Intends to Lead The Pack In Stem Cell Therapies!
  • Governments, medical facilities, and patients are concerned over the economical viability and clinical efficacy of regenerative medicine and stem cell research.
  • Looking at a handful of stem cell therapies, the study showed that regenerative medicine is likely to be more impactful in cost-effectiveness compared to other conventional health technologies.
  • The study also noted that for stem cell treatment of scoliosis, the level of cost-effectiveness was acceptable to policymakers and healthcare purchasers.

Argá Medtech Initiates First-in-Human Trial to Assess the Safety and Effectiveness of Coherent Sine Wave Electroporation in Patients with Atrial Fibrillation

Retrieved on: 
Wednesday, October 26, 2022
Arrhythmia, Atrial fibrillation, Unipolar, Breathe Me, Lethargy, CEO, Physician, CSE, Clinical trial, PFA, Femoral vein, Quality of life, Medtech, Pain scale, Esophagus, CA, Tissue, Research, GLOBE, Lists of Palestinian rocket attacks on Israel, Bipolar, Efficiency, Heart, Electroporation, Palpitations, Medical imaging, Medical device, Patient, Ventricular fibrillation

EPALINGES, Switzerland, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Arg Medtech announced today that it has begun enrollment in their First-in-Human Clinical Trial Coherent Sine Burst Electroporation (CSE) System Pilot Study in Patients with Atrial Fibrillation (BURST-AF).

Key Points: 
  • EPALINGES, Switzerland, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Arg Medtech announced today that it has begun enrollment in their First-in-Human Clinical Trial Coherent Sine Burst Electroporation (CSE) System Pilot Study in Patients with Atrial Fibrillation (BURST-AF).
  • The study is designed to test the acute safety and efficiency of the Arg Medtech CSE Ablation System in the treatment of atrial fibrillation (AFib).
  • The CSE system consists of a configurable (circular, linear, and focal) ablation catheter and pulsed field ablation (PFA) generator.
  • In contrast to all other PFA waveforms, CSE employs a unique sinusoidal wave instead of a square wave.

Avadel Presents New Real-World Data Describing Demographic Characteristics and Comorbidities of Patients with Narcolepsy at ANA 2022

Retrieved on: 
Monday, October 24, 2022
People, Paced Auditory Serial Addition Test, Female, Dysthymia, Migraine, Mayo Clinic, Prevalence, American Neurological Association, Narcolepsy, Compartment syndrome, Carpal tunnel syndrome, Places in the United States with notable demographic characteristics, ANA, Fibromyalgia, Patient, Sleep, Depression, Mortality, Myalgia, Partnership, Nasdaq, Pain disorder, Sex, Pain, GLOBE, Anxiety, Literature, Insomnia, Center, Pain scale, Obstructive sleep apnea, Health information management, Pharmaceutical industry, Retail

DUBLIN, Ireland, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced new real-world data identifying demographic characteristics and comorbidities of patients with narcolepsy. These results, along with three encore presentations, were presented at the American Neurological Association (ANA) annual meeting, taking place October 22-25, 2022.

Key Points: 
  • These results, along with three encore presentations, were presented at the American Neurological Association (ANA) annual meeting, taking place October 22-25, 2022.
  • These data mark the first time we are analyzing aggregate information about patients with narcolepsy receiving treatment within the Mayo Clinic system over the last 20 years.
  • The retrospective analysis was conducted in partnership with Mayo Clinic and real-world evidence vendor nFerence using electronic health records to identify people living with narcolepsy between 2000 and 2020 and describe their demographic characteristics and comorbidities.
  • A matched control cohort was used to account for differences in demographics, care utilization and severity of illness.

Neodymium-Iron-Boron Magnet Global Market Report 2022: Rising Application in Orthodontic Treatments, Molar Distillation, and Palatal Expansion Drives Sector

Retrieved on: 
Wednesday, October 26, 2022
Magnet, Astronaut, Computer, Arthritis, Efficiency, Microwave, Wound healing, Employment, CAGR, Neodymium, Neodymium magnet, Headache, Motion, Wind, Iron, Boron, Robotics, Insomnia, Pain scale, ACS, Magnetic resonance imaging, Renewable energy, Rare-earth element, Electric motor, Growth

DUBLIN, Oct. 26, 2022 /PRNewswire/ -- The "Neodymium-Iron-Boron Magnet Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Oct. 26, 2022 /PRNewswire/ -- The "Neodymium-Iron-Boron Magnet Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global neodymium-iron-boron magnet market size reached US$ 13.6 Billion in 2021.
  • Looking forward, the publisher expects the market to reach US$ 21.1 Billion by 2027, exhibiting a CAGR of 7.59% during 2021-2027.
  • This, coupled with the rising application of these magnets as a motion-generating device in orthodontic treatments, molar distillation, and palatal expansion, is propelling the growth of the market.

NeuroOne® Receives FDA 510(k) Clearance to Market its Evo® sEEG System for Less than 30 Day Use

Retrieved on: 
Tuesday, October 25, 2022
U.S. Securities and Exchange Commission, Drug Quality and Security Act, Risk, Dystonia, Skull, DBS, Growth, Hyperreflexia, Deep brain stimulation, Patient, Parkinson's disease, Seeg, Electrode, EEG, Security (finance), EDEN, NMTC, Lists of diseases, Multimedia, Securities Act of 1933, Partnership, Nasdaq, Technology, Food, Company, Food and Drug Administration, Epilepsy, CEO, Securities Exchange Act of 1934, Letter, Pain scale, Phrase, Noise, Clinical trial, Brain, Chronic pain, Evo, Terminology, FDA, COVID-19, Medical device

EDEN PRAIRIE, Minn., Oct. 25, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (NeuroOne or the Company), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance to market its Evo sEEG Electrode technology for temporary (less than 30 days) use with recording, monitoring, and stimulation equipment for the recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain.

Key Points: 
  • On August 9, 2022, the Company announced it had resubmitted its 510(k) application to the FDA for less than 30 day use, which included additional biocompatibility testing as requested by the FDA.
  • On October 20, 2022, the Company received an FDA clearance letter stating that the Evo sEEG System is substantially equivalent to the predicate device and may be marketed in the United States.
  • "I am extremely proud of the entire NeuroOne team and their relentless pursuit of this clearance.
  • The Evo sEEG System represents the Company's second FDA 510(k) cleared product.

Inspired Spine Opens New Clinic in Burnsville, MN

Retrieved on: 
Wednesday, October 19, 2022
Trigger, Crookston, Patient, Back pain, Spine, Multimedia, PM, Pain scale, Bookbinding, Rehabilitation, Acupuncture

BURNSVILLE, Minn., Oct. 19, 2022 /PRNewswire/ -- Inspired Spine announced today the opening of their newly remodeled clinic in Burnsville.

Key Points: 
  • BURNSVILLE, Minn., Oct. 19, 2022 /PRNewswire/ -- Inspired Spine announced today the opening of their newly remodeled clinic in Burnsville.
  • The 7,900 square foot clinic is an extreme upgrade from their current clinic of 2,500 square feet.
  • Inspired Spine CMO Dr. Hamid Abbasi explains, "This is another huge step for Inspired Spine to provide excellent care for our patients.
  • If you have questions or would like to learn more about Inspired Spine, please visit inspiredspine.com or call 952-405-6714.